Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TAS2R8 | Q9NYW2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314922 | 0.83 | TDP1 (0.49) | TDP1L3MBTL1P2RX7GAAMEN1 | |
| SCHEMBL14302719 | 0.75 | P2RX7 (0.50) | TDP1P2RX7MEN1KMT2AALDH1A1 | |
| SCHEMBL10189865 | 0.74 | P2RX7 (0.49) | TDP1P2RX7MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL315726 | 0.73 | P2RX7 (0.48) | TDP1P2RX7MEN1KMT2AALDH1A1 | |
| SCHEMBL4182412 | 0.72 | TDP1 (0.47) | TDP1L3MBTL1P2RX7GAAMEN1 | |
| SCHEMBL314801 | 0.70 | MEN1 (0.45) | TDP1L3MBTL1P2RX7GAAMEN1 | |
| SCHEMBL12500526 | 0.70 | P2RX7 (0.44) | TDP1L3MBTL1P2RX7GAAMEN1 | |
| SCHEMBL5001136 | 0.69 | PPARA (0.53) | L3MBTL1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL5001135 | 0.69 | PPARA (0.53) | L3MBTL1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL12752068 | 0.69 | P2RX7 (0.39) | TDP1L3MBTL1P2RX7GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | TDP1 4263/4885L3MBTL1 4863/4885P2RX7 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.